These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 25154927)

  • 1. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis.
    Lan Y; Lam JT; Siu GK; Yam WC; Mason AJ; Lam JK
    Tuberculosis (Edinb); 2014 Dec; 94(6):678-89. PubMed ID: 25154927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro.
    Silva S; Santos-Silva A; da Costa JMC; Vale N
    J Glob Antimicrob Resist; 2019 Dec; 19():132-135. PubMed ID: 31154008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
    Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
    Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
    Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
    Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
    Martins M; Viveiros M; Couto I; Amaral L
    Int J Tuberc Lung Dis; 2009 May; 13(5):569-73. PubMed ID: 19383188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis.
    Shao Z; Tam KK; Achalla VPK; Woon ECY; Mason AJ; Chow SF; Yam WC; Lam JKW
    Int J Pharm; 2024 Apr; 654():123960. PubMed ID: 38447778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates.
    AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F
    Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
    Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of tetracycline analogs against multidrug-resistant and extensive drug resistance clinical isolates of Mycobacterium tuberculosis.
    Zhang C; Ouyang Q; Zhou X; Huang Y; Zeng Y; Deng L; Lin D; Zheng W
    Tuberculosis (Edinb); 2023 May; 140():102336. PubMed ID: 36963294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
    Gokarn K; Pal RB
    BMC Complement Altern Med; 2017 Mar; 17(1):161. PubMed ID: 28327117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
    Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
    BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Resistance Characteristics of
    Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
    Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance mechanisms and drug susceptibility testing for tuberculosis.
    Miotto P; Zhang Y; Cirillo DM; Yam WC
    Respirology; 2018 Dec; 23(12):1098-1113. PubMed ID: 30189463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical against molecular-genetic methods for susceptibility testing of antituberculotics.
    Porvaznik I; Mokry J; Solovic I
    Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
    Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
    Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.